Allotransplant (allo- meaning "other" in Greek) is the transplantation of cells, tissues, or organs to a recipient from a genetically non-identical donor of the same species.
An allogenic bone marrow transplant can result in an immune attack on the recipient, called graft-versus-host disease.
Screening for pathology and risk factors for communicable diseases such as HIV and Hepatitis B and C is then conducted.
In order to ensure the quality of donor tissue and reduce contamination and disease transmission risks, three regulations addressing manufacturing activities associated with human cells, tissues, and cellular and tissue-based products (HCT/Ps) were promulgated in May 2005: As with many operations, allotransplantation risks some side effects.
A limiting factor in tissue allotransplantation for reconstructive surgery deals with the side effects of immunosuppression (metabolic disorders, malignancies, opportunistic infections) which is a predominant issue.